Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6afbd19f560437f5d406b637c676c322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90b09b541235ea9c29ed65a19b8cf1a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b603ecd95b3b1497ae9f30752a676c0e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a0e25c5a3ddb10fe27974341ff172cd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-19 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-741 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-741 |
filingDate |
2020-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b412f14d79fc14024e89e96371e37890 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f91d3ce2b08354b8bc8d20807c60e7c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c253a6f7b3433d342a3d97abdbb97047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9b72603dc7c6f91e9e342aaaca726f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74fd43fbd47649ccb2c1184eae35bb70 |
publicationDate |
2021-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2021005059-A1 |
titleOfInvention |
Modified escherichia coli strain nissle and treatment of gastrointestinal disorder |
abstract |
The invention relates to the field of modified Escherichia coli strain Nissle 1917 (EcN) and its use for treating gastro-intestinal disorders. The invention is based on the study of the mechanisms implicated in the probiotic properties of the Escherichia coli strain Nissle 1917 (EcN). This study has allowed the inventors to decouple the probiotic activity of EcN from its genotoxic activity by demonstrating that EcN ClbP protein, the enzyme that activates the genotoxin colibactin, is also required for the siderophore-microcins activity of probiotic EcN, but interestingly, not its enzymatic domain that cleaves precolibactin to form active colibactin. Furthermore, inventors demonstrate in an in vivo animal model infected by a bacterial pathogen that administration of an EcN modified strain with clbP gene encoding ClbP protein inactive for the peptidase domain, is non-genotoxic (do not produce colibactin) but keeps the bacterial antagonist activity, and reduces colonization and virulence of the pathogen by maintaining the siderophore-microcin production. Thus this study opens the way to safe use of EcN and accordingly the present invention provides an Escherichia coli strain Nissle 1917 (EcN) bacterium carrying a gene encoding ClbP protein which is inactive for the peptidase domain, and its use as a drug and more particularly for use in the treatment of gastro-intestinal disease. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113186140-A |
priorityDate |
2019-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |